TrialJournal of translational medicine2016

GNAS mutations as prognostic biomarker in patients with relapsed peritoneal pseudomyxoma receiving metronomic capecitabine and bevacizumab: a clinical and translational study.

Filippo Pietrantonio et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.